ArticleInternational journal of clinical and experimental pathology2019
Association of treRNA with lymphatic metastasis and poor prognosis in colorectal cancer.
Article in International journal of clinical and experimental pathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 2 citations in OpenAlex.
- Biomarkers (mRNAs and Non-Coding RNAs) for the Diagnosis and Prognosis of Colorectal Cancer - From the Body Fluid to Tissue Level.Frontiers in oncology · 2021Review
- Detecting Prognosis Risk Biomarkers for Colon Cancer Through Multi-Omics-Based Prognostic Analysis and Target Regulation Simulation Modeling.Frontiers in genetics · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere is an emerging concept that long noncoding RNAs (lncRNAs) are involved in tumorigenesis and could be used as biomarkers. However, the clinical significance of human translational regulatory lncRNA (treRNA) in CRC is largely unknown. The purpose of the study was to examine the value of treRNA as a biomarker in colorectal cancer patients.
methodstreRNA expression was studied in 78 tumors and adjacent tissues in colorectal cancer patients using quantitative real-time PCR.
resultstreRNA was found to be highly expressed in colorectal cancer tissue in contrast to adjacent tissue (P<0.05). Moreover, positive correlation was found between high treRNA expression and lymph node metastasis (P<0.05). Patients with high treRNA expression were found with compromised overall survival (OS) compared with the low treRNA expression group, according to Kaplan-Meier analysis. Moreover, Cox regression model analysis suggested high expression of treRNA as an independent poor prognostic factor for CRC patients.
conclusionsOverexpression of treRNA could be associated with lymphatic metastasis and compromised survival of CRC. treRNA has potential to be used as a new biomarker for CRC lymphatic metastasis and survival.
Indexed as
Identifiers
31933996PMC6947107W3019845953What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.